Imatinib might constitute a treatment option for lung involvement in COVID-19

doi:10.1016/j.autrev.2020.102565

Comment

. 2020 Jul;19(7):102565.

doi: 10.1016/j.autrev.2020.102565. Epub 2020 May 3.

Imatinib might constitute a treatment option for lung involvement in COVID-19

Affiliations

¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: david.bernal@salud.madrid.org.
² Castilla La Nueva Primary Health Care Center, Madrid, Spain.. Electronic address: beatriz.jaenes@salud.madrid.org.
³ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: alejandro.morales@salud.madrid.org.
⁴ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: josemanuel.ruiz@salud.madrid.org.
⁵ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: vgbermudez@salud.madrid.org.
⁶ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: begona.frutos@salud.madrid.org.
⁷ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: anai.farfan@salud.madrid.org.
⁸ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: cristina.ancos@salud.madrid.org.
⁹ Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Madrid, Spain.. Electronic address: fernando.bermejo@salud.madrid.org.
¹⁰ Department of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: mgarciagil@salud.madrid.org.
¹¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: antonio.zapatero@salud.madrid.org.
¹² Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: juanvictor.san@salud.madrid.org.

PMID: 32376403
PMCID: PMC7252139
DOI: 10.1016/j.autrev.2020.102565

Comment

Imatinib might constitute a treatment option for lung involvement in COVID-19

David Bernal-Bello et al. Autoimmun Rev. 2020 Jul.

. 2020 Jul;19(7):102565.

doi: 10.1016/j.autrev.2020.102565. Epub 2020 May 3.

Affiliations

¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: david.bernal@salud.madrid.org.
² Castilla La Nueva Primary Health Care Center, Madrid, Spain.. Electronic address: beatriz.jaenes@salud.madrid.org.
³ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: alejandro.morales@salud.madrid.org.
⁴ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: josemanuel.ruiz@salud.madrid.org.
⁵ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: vgbermudez@salud.madrid.org.
⁶ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: begona.frutos@salud.madrid.org.
⁷ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: anai.farfan@salud.madrid.org.
⁸ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: cristina.ancos@salud.madrid.org.
⁹ Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Madrid, Spain.. Electronic address: fernando.bermejo@salud.madrid.org.
¹⁰ Department of Hospital Pharmacy, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: mgarciagil@salud.madrid.org.
¹¹ Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: antonio.zapatero@salud.madrid.org.
¹² Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain.. Electronic address: juanvictor.san@salud.madrid.org.

PMID: 32376403
PMCID: PMC7252139
DOI: 10.1016/j.autrev.2020.102565

No abstract available

PubMed Disclaimer

Comment on

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.
McGonagle D, Sharif K, O'Regan A, Bridgewood C. McGonagle D, et al. Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3. Autoimmun Rev. 2020. PMID: 32251717 Free PMC article. Review.

Cited by

Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease.
Karimi M, Bahadoram M, Mafakher L, Rastegar M. Karimi M, et al. Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):387-392. doi: 10.1016/j.htct.2023.06.007. Epub 2023 Aug 10. Hematol Transfus Cell Ther. 2024. PMID: 37652804 Free PMC article.
Ofeleein i mi Vlaptin-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.
Kountouras J, Gialamprinou D, Kotronis G, Papaefthymiou A, Economidou E, Soteriades ES, Vardaka E, Chatzopoulos D, Tzitiridou-Chatzopoulou M, Papazoglou DD, Doulberis M. Kountouras J, et al. Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309. Medicina (Kaunas). 2022. PMID: 35208631 Free PMC article. Review.
COVID-19 therapy: What weapons do we bring into battle?
de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA. de Almeida SMV, et al. Bioorg Med Chem. 2020 Dec 1;28(23):115757. doi: 10.1016/j.bmc.2020.115757. Epub 2020 Sep 10. Bioorg Med Chem. 2020. PMID: 32992245 Free PMC article.
Drug-Induced Liver Disturbance During the Treatment of COVID-19.
Zhai G, Li M, Wang Y, Wu J. Zhai G, et al. Front Pharmacol. 2021 Aug 18;12:719308. doi: 10.3389/fphar.2021.719308. eCollection 2021. Front Pharmacol. 2021. PMID: 34483929 Free PMC article. Review.
Review of pharmacologic and immunologic agents in the management of COVID-19.
Ungogo MA, Mohammed M, Umar BN, Bala AA, Khalid GM. Ungogo MA, et al. Biosaf Health. 2021 Jun;3(3):148-155. doi: 10.1016/j.bsheal.2021.01.001. Epub 2021 Jan 9. Biosaf Health. 2021. PMID: 33458647 Free PMC article. Review.

See all "Cited by" articles

References

1. McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102537. published online April 3. - DOI - PMC - PubMed
1. Yao X., Ye F., Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. published online March 9. - DOI - PMC - PubMed
1. Yao T., Qian J., Zhu W., Wang Y., Wang G. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020 doi: 10.1002/jmv.25729. published online February 27. - DOI - PMC - PubMed
1. Richardson P., Griffin I., Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. doi: 10.1016/S0140-6736(20)30304-4. - DOI - PMC - PubMed
1. Mehta P., McAuley D.F., Brown M. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 doi: 10.1016/S0140-6736(20)30628-0. published online March 16. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

[1] McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102537. published online April 3. - DOI - PMC - PubMed

[2] McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020 doi: 10.1016/j.autrev.2020.102537. published online April 3. - DOI - PMC - PubMed

[3] Yao X., Ye F., Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. published online March 9. - DOI - PMC - PubMed

[4] Yao X., Ye F., Zhang M. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa237. published online March 9. - DOI - PMC - PubMed

[5] Yao T., Qian J., Zhu W., Wang Y., Wang G. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020 doi: 10.1002/jmv.25729. published online February 27. - DOI - PMC - PubMed

[6] Yao T., Qian J., Zhu W., Wang Y., Wang G. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020 doi: 10.1002/jmv.25729. published online February 27. - DOI - PMC - PubMed

[7] Richardson P., Griffin I., Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. doi: 10.1016/S0140-6736(20)30304-4. - DOI - PMC - PubMed

[8] Richardson P., Griffin I., Tucker C. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. doi: 10.1016/S0140-6736(20)30304-4. - DOI - PMC - PubMed

[9] Mehta P., McAuley D.F., Brown M. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 doi: 10.1016/S0140-6736(20)30628-0. published online March 16. - DOI - PMC - PubMed

[10] Mehta P., McAuley D.F., Brown M. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 doi: 10.1016/S0140-6736(20)30628-0. published online March 16. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Imatinib might constitute a treatment option for lung involvement in COVID-19

Affiliations

Imatinib might constitute a treatment option for lung involvement in COVID-19

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources